Ask AI
Rationale for TROP2 ADCs in TNBC

CME

Foundations of ADC Therapy and the Clinical Rationale for Targeting TROP-2 in TNBC

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: July 10, 2026

Expiration: January 09, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer (KEYNOTE-355). N Engl J Med. 2022;387:217-226.
  2. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer (ASCENT). N Engl J Med. 2021;384:1529-1541.
  3. Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer (ASCENT-04/KEYNOTE-D19). N Engl J Med. 2026;394:354-366.
  4. Cortes J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer (ASCENT-03). N Engl J Med. 2025;393:1912-1925.
  5. Dent R, Shao Z, Schmid P, et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomized, open-label, international, phase III trial. Ann Oncol. 2026;S0923-7534(26)00130-4.
  6. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327-344.
  7. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6:84-105.
  8. Jeon Y, Jo U, Hong J, et al. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. BMC Cancer. 2022;22:1014.
  9. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody-drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35:2141-2148.
  10. Rugo HS, Bardia A, Marme F, et al. Sacituzumab govitecan vs treatment of physician’s choice: efficacy by Trop-2 expression in the TROPiCS-02 study of patients with HR+/HER2- metastatic breast cancer. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS1-11.
  11. Izci H, Punie K, Waumans L, et al. Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer. Sci Rep. 2022;12:22498.
  12. Bardia A, Rugo HS, Tolaney SM, et al. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by HER2 and TROP-2 expression. J Clin Oncol. 2024;42:1738-1744.
  13. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2026.
  14. Datopotamab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2026.
  15. Li N, Chen H, Zuo Y, et al. New insights into the bystander effect of antibody-drug conjugates. Exp Hematol Oncol. 2025;14:41.
  16. Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 2021;11:2436-2445.